Close Menu

Acuity Says IND Gets FDA Ok

Acuity Pharmaceuticals has said that its investigational new drug application for its siRNA-based treatment for age-related macular degeneration has been approved by US regulators.

According to a statement from Acuity’s president and CEO Dale Pfost, “the FDA usually reviews INDs in one month, and in the absence of notification to the contrary an IND may open and recruitment of patients commence. Acuity’s IND is now open, and patients are planned to begin to be treated in October,” he added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.